Literature DB >> 6469510

Macromolecular DNA-damage in murine and human leukemic and lymphoid cells after in vitro exposure to ASTA Z 7557 (INN mafosfamide).

R Osieka, R Pannenbäcker, C G Schmidt.   

Abstract

Cyclophosphamide (CPA) is widely used against leukemic and lymphoproliferative diseases, but in vitro studies on response to this agent so far have been limited to instable derivatives with poor galenic properties. ASTA Z 7557 is a newly synthesized "activated cyclophosphamide" that circumvents the need for hepatic activation and has good stability. The critical cytotoxic lesions after exposure to bifunctional alkylating agents presumably are DNA interstrand crosslinks (ISC). We have, therefore, examined the formation and apparent removal of ISC after in vitro treatment with ASTA Z 7557 by use of the highly sensitive alkaline elution technique. Survival of murine L1210 cells was determined after 1 hour in vitro exposure with a D 37 value of 5.7 micrograms/ml (from the initial shoulder part of the survival curve) and a Do value of 1.5 micrograms/ml (from the exponential part of the curve). Previous labelling of L1210 cells by 125IUdR simplified the alkaline elution procedure but there was some cytotoxicity of the radiochemical itself with a reduction of cloning efficiency from 77% to 61%. The maximum of ISC was observed at 6 h after initiation of treatment with much of the damage apparently removed at 24 h. The simultaneous presence of DNA single strand breaks (SSB), however, confounds the analysis of DNA damage at 24 h and early cytolysis and unaided death of human lymphocytes often preclude the analysis of macromolecular damage at this time. Human peripheral blood cells isolated from patients with leukemic or lymphoproliferative diseases showed a remarkable heterogeneity with regard to the formation of ISC at 3 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6469510     DOI: 10.1007/bf00232346

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  15 in total

1.  Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.

Authors:  N Brock
Journal:  Cancer Treat Rep       Date:  1976-04

2.  Mechanism of cyclophosphamide transport by L5178Y lymphoblasts in vitro.

Authors:  G J Goldenberg; H B Land; D V Cormack
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

3.  Repair of DNA interstrand crosslinks after busulphan. A possible mode of resistance.

Authors:  P Bedford; B W Fox
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Differential cytotoxicity and DNA cross-linking produced by polymeric and monomeric activated analogues of cyclophosphamide in mouse L1210 leukemia cells.

Authors:  L M Ramonas; L C Erickson; W Klesse; K W Kohn; D S Zaharko
Journal:  Mol Pharmacol       Date:  1981-03       Impact factor: 4.436

5.  Therapeutic implications of iodine-125 cytotoxicity.

Authors:  W D Bloomer; W H McLaughlin; S J Adelstein
Journal:  Int J Radiat Oncol Biol Phys       Date:  1982-11       Impact factor: 7.038

6.  Extracts of chronic lymphocytic leukemia lymphocytes have a high level of DNA repair activity fo O6-methylguanine.

Authors:  E A Waldstein; E H Cao; M E Miller; E P Cronkite; R B Setlow
Journal:  Proc Natl Acad Sci U S A       Date:  1982-08       Impact factor: 11.205

7.  Comparative studies of DNA cross-linking and cytotoxicity in Burkitt's lymphoma cell lines treated with cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.

Authors:  J M Ducore; L C Erickson; L A Zwelling; G Laurent; K W Kohn
Journal:  Cancer Res       Date:  1982-03       Impact factor: 12.701

8.  Permeation of cyclophosphamide (NSC-26271) metabolites into tumor cells.

Authors:  U Draeger; H J Hohorst
Journal:  Cancer Treat Rep       Date:  1976-04

9.  Colchicine ultrasensitivity of lymphocytes in chronic lymphocytic leukaemia.

Authors:  G Wetherley-Mein; A E Thomson; T W O'Connor; W E Peel; A K Singh
Journal:  Br J Haematol       Date:  1983-05       Impact factor: 6.998

10.  Effect of dose, schedule, and route of administration on the in vivo toxicity and antitumor activity of two activated sulfhydryl derivatives of cyclophosphamide.

Authors:  L M Ramonas; L C Erickson; H Ringsdorf; D S Zaharko
Journal:  Cancer Res       Date:  1980-10       Impact factor: 12.701

View more
  2 in total

Review 1.  Bone marrow purging with mafosfamide--a critical survey.

Authors:  H Sindermann; M Peukert; P Hilgard
Journal:  Blut       Date:  1989-11

2.  Possible role of histone acetylation and histone H1(0) replacement for the initiation of replication in regenerating rat liver.

Authors:  G Weiss; H Talasz; B Puschendorf
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.